The filing by Outlook Therapeutics to potentially offer and sell a significant amount of common stock could lead to increased liquidity for the company, which might be positive in terms of financial flexibility. However, the introduction of additional shares into the market typically results in dilution for existing shareholders, which can lead to a negative perception among investors and potentially decrease the stock price in the short term.